AU2020398858B2 - Treating cognitive disorders using trapidil - Google Patents

Treating cognitive disorders using trapidil

Info

Publication number
AU2020398858B2
AU2020398858B2 AU2020398858A AU2020398858A AU2020398858B2 AU 2020398858 B2 AU2020398858 B2 AU 2020398858B2 AU 2020398858 A AU2020398858 A AU 2020398858A AU 2020398858 A AU2020398858 A AU 2020398858A AU 2020398858 B2 AU2020398858 B2 AU 2020398858B2
Authority
AU
Australia
Prior art keywords
per day
trapidil
pharmaceutically acceptable
acceptable salt
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020398858A
Other languages
English (en)
Other versions
AU2020398858A1 (en
Inventor
Aarash BORDBAR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sinopia Biosciences Inc
Original Assignee
Sinopia Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sinopia Biosciences Inc filed Critical Sinopia Biosciences Inc
Publication of AU2020398858A1 publication Critical patent/AU2020398858A1/en
Application granted granted Critical
Publication of AU2020398858B2 publication Critical patent/AU2020398858B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2020398858A 2019-12-02 2020-12-01 Treating cognitive disorders using trapidil Active AU2020398858B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962942645P 2019-12-02 2019-12-02
US62/942,645 2019-12-02
PCT/US2020/062751 WO2021113266A1 (en) 2019-12-02 2020-12-01 Treating cognitive disorders using trapidil

Publications (2)

Publication Number Publication Date
AU2020398858A1 AU2020398858A1 (en) 2022-06-30
AU2020398858B2 true AU2020398858B2 (en) 2026-02-19

Family

ID=76221925

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020398858A Active AU2020398858B2 (en) 2019-12-02 2020-12-01 Treating cognitive disorders using trapidil

Country Status (7)

Country Link
US (1) US20220378794A1 (https=)
EP (1) EP4069239A4 (https=)
JP (2) JP7656608B2 (https=)
CN (1) CN115397425A (https=)
AU (1) AU2020398858B2 (https=)
CA (1) CA3163242A1 (https=)
WO (1) WO2021113266A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10695338B2 (en) * 2015-05-07 2020-06-30 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Cancer treatment via repositioned tricyclic anti-depressant-like drugs as anti-cancer agents and new combinations of such drugs
MX2022011879A (es) 2020-03-26 2023-01-11 Sinopia Biosciences Inc Derivados de trapidilo marcados isotopicamente.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190328741A1 (en) * 2016-04-04 2019-10-31 Sinopia Biosciences, Inc. Treating extrapyramidal syndrome using trapidil

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02212488A (ja) * 1989-02-13 1990-08-23 Shinichiro Shimizu トリアゾールピリミジン誘導体
AU2004272437A1 (en) 2003-09-09 2005-03-24 Ono Pharmaceutical Co., Ltd. CRF antagonists and heterobicyclic compounds
WO2012060844A1 (en) * 2010-11-05 2012-05-10 Biotie Therapies, Inc A2a antagonists as cognition and motor function enhancers
JP2021524837A (ja) * 2018-04-13 2021-09-16 ヒールクス リミテッドＨｅａｌｘ Ｌｉｍｉｔｅｄ 脆弱ｘ症候群のためのキット、組成物および併用療法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190328741A1 (en) * 2016-04-04 2019-10-31 Sinopia Biosciences, Inc. Treating extrapyramidal syndrome using trapidil

Also Published As

Publication number Publication date
CA3163242A1 (en) 2021-06-10
EP4069239A4 (en) 2023-11-29
AU2020398858A1 (en) 2022-06-30
CN115397425A (zh) 2022-11-25
WO2021113266A1 (en) 2021-06-10
JP7656608B2 (ja) 2025-04-03
JP2025111439A (ja) 2025-07-30
EP4069239A1 (en) 2022-10-12
JP2023504004A (ja) 2023-02-01
US20220378794A1 (en) 2022-12-01

Similar Documents

Publication Publication Date Title
US20200246259A1 (en) Methods of treating abc-dlbcl using inhibitors of brutons tyrosine kinase
EP2056818B1 (en) Compositions and methods for neuroprotection
US12268691B2 (en) Treating extrapyramidal syndrome using trapidil
US20100298394A1 (en) Antifungal agents as neuroprotectants
JP2025111439A (ja) トラピジルを使用した認知障害の治療
US20220079927A1 (en) Nicorandil derivatives
US8883199B2 (en) Administration regime for N-hydroxy-4-{2-[3-(N,N-dimethylaminomethyl)benzofuran-2- ylcarbonylamino]ethoxy}benzamide
US20190111059A1 (en) Compositions and methods for treating autism spectrum disorder
BR112021010720A2 (pt) Métodos para tratar ou prevenir gota ou hiperuricemia
WO2017011314A1 (en) Btk and hdac combinations
US20170360805A1 (en) Motor-associated neurodegenerative disease and methods of treatment
HK40004660A (en) Treating levodopa-induced dyskinesia using trapidil